Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients

Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Slawek, Deepika, Altshuler, Diana, Dubrovskaya, Yanina, Louie, Eddie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632526/
https://www.ncbi.nlm.nih.gov/pubmed/29026871
http://dx.doi.org/10.1093/ofid/ofx184
_version_ 1783269720195072000
author Slawek, Deepika
Altshuler, Diana
Dubrovskaya, Yanina
Louie, Eddie
author_facet Slawek, Deepika
Altshuler, Diana
Dubrovskaya, Yanina
Louie, Eddie
author_sort Slawek, Deepika
collection PubMed
description Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.
format Online
Article
Text
id pubmed-5632526
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56325262017-10-12 Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients Slawek, Deepika Altshuler, Diana Dubrovskaya, Yanina Louie, Eddie Open Forum Infect Dis Brief Report Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy. Oxford University Press 2017-10-07 /pmc/articles/PMC5632526/ /pubmed/29026871 http://dx.doi.org/10.1093/ofid/ofx184 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Slawek, Deepika
Altshuler, Diana
Dubrovskaya, Yanina
Louie, Eddie
Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title_full Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title_fullStr Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title_full_unstemmed Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title_short Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
title_sort tigecycline as a second-line agent for legionnaires’ disease in severely ill patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632526/
https://www.ncbi.nlm.nih.gov/pubmed/29026871
http://dx.doi.org/10.1093/ofid/ofx184
work_keys_str_mv AT slawekdeepika tigecyclineasasecondlineagentforlegionnairesdiseaseinseverelyillpatients
AT altshulerdiana tigecyclineasasecondlineagentforlegionnairesdiseaseinseverelyillpatients
AT dubrovskayayanina tigecyclineasasecondlineagentforlegionnairesdiseaseinseverelyillpatients
AT louieeddie tigecyclineasasecondlineagentforlegionnairesdiseaseinseverelyillpatients

Ejemplares similares